PCAS : SUSTAINED GROWTH IN NET SALES FOR THE FIRST HALF OF 2015

Net sales for the first half of 2015 up by 6.4%, 
fueled by the driving force of the company's healthcare activities

Longjumeau; July 16, 2015: PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales for the first half of 2015.

As of June 30, 2015, the PCAS Group had generated consolidated net sales of €90.3 million, representing a growth of 6.4% compared to the same period during the previous financial year.

Mr Vincent Touraille, Chief Executive Officer of PCAS, comments: "We are satisfied with the direction in which our net sales have been heading by the end of the first half of the year. The second half of the year should confirm and even see an increase in this positive trend, especially by pursuing the strong driving force in our healthcare markets. "

Comments by business line:

• Pharmaceutical synthesis (2/3 of the Group's net sales)

The pharmaceutical synthesis business is up 10.7% on H1 2014 at €60.5 million, driven by a strong market environment, especially in the US. Recent launches and advanced clinical trials of new treatments are powering the active substances activity developed in partnership with leading laboratories and biotech companies. Furthermore, sales of proprietary PCAS molecules are clearly targeting different segments and geographical areas, and are also taking advantage of a better product mix.

• Fine specialty chemicals (1/3 of the Group's net sales))

Net sales of fine specialty chemicals amounted to €29.8 million, down -1.3% on June 30, 2014. While business is growing in the performance chemicals and new technologies markets, driven by increasing market shares in Germany and Asia. The overall trend in the Group's net sales is being affected by the negative contribution of the fragrances-flavors-cosmetics business line.

Prospects for the current year

Thanks to the current high level of demand from customers and the favorable exchange rate parity for major export markets, the Group is maintaining an optimistic outlook for the next few months, especially with the sound performance of the North American market. Based on the first half of the year and available sales information, the second half should confirm and even see an increase in this trend with a level of growth in our net sales throughout 2015 greater than the level registered during the first six months of the year.

Prochaine publication financière :
Résultats semestriels, le 8 septembre 2015

PCAS est le spécialiste du développement et de la production de molécules complexes pour les Sciences de la vie et les Technologies innovantes. Avec 7% de son chiffre d'affaires dédié à la R&D et une large implantation internationale, PCAS est le partenaire industriel privilégié des grands groupes mondiaux leaders sur leurs marchés. La Société propose une gamme croissante de produits et solutions propriétaires dans des segments de pointe et comprend également deux filiales à très fort potentiel : Protéus dans la biotechnologie et Enersens dans l'isolation haute performance. Dotée d'un niveau particulièrement élevé d'exigence, PCAS a réalisé en 2014 un chiffre d'affaires de 166 M€ et emploie près de 900 collaborateurs répartis dans 6 pays.
Pour en savoir plus sur PCAS : www.pcas.com:
http://www.pcas.com/